Synthesis and Characterization of a Silica-Based Drug Delivery System for Spinal Cord Injury Therapy
- PDF / 2,929,432 Bytes
- 20 Pages / 595.276 x 790.866 pts Page_size
- 40 Downloads / 168 Views
ARTICLE
Cite as Nano-Micro Lett. (2019) 11:23 Received: 5 January 2019 Accepted: 19 February 2019 © The Author(s) 2019
https://doi.org/10.1007/s40820-019-0252-6
Synthesis and Characterization of a Silica‑Based Drug Delivery System for Spinal Cord Injury Therapy Guodong Sun2, Shenghui Zeng1, Xu Liu1, Haishan Shi1, Renwen Zhang3, Baocheng Wang4, Changren Zhou1, Tao Yu1 * * Tao Yu, [email protected] College of Chemistry and Material Sciences, Jinan University, Guangzhou 510632, People’s Republic of China 2 Department of Orthopedics, First Affiliated Hospital, Jinan University, Guangzhou 510632, People’s Republic of China 1
3
4
College of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, People’s Republic of China Tsinghua‑Berkeley Shenzhen Institute, Tsinghua University, Shenzhen 518055, People’s Republic of China
HIGHLIGHTS • With good biocompatibility, a silica-based drug delivery system was prepared and used effectively in vivo to prolong the duration of drug treatment. • The prepared system can target spinal cord injury directly. Additionally, due to its small size (approximately 100 nm), it can penetrate the blood-spinal cord barrier. • This system reduced the expression of interleukin-17 (IL-17) and IL-17-related inflammatory factors and can protect neurons and promote the recovery of spinal cord injury.
ABSTRACT Acute inflammation is a central component in the progression of spinal cord injury (SCI). Anti-inflammatory drugs used in the clinic are often administered sys‑
temically at high doses, which can paradoxically increase inflammation and result in drug toxicity. A cluster-like mesoporous silica/arctigenin/CAQK composite (MSN-FC@ARCG) drug delivery system was designed to avoid systemic side effects of high-dose therapy
Blood-Brain barrier
by enabling site-specific drug delivery to the spinal cord. In this nanosystem, mesoporous silica was modified with the FITC fluorescent molecule and CAQK peptides that target brain injury and SCI sites. The size of the nanocarrier was kept at approximately 100 nm to enable penetration of the blood–brain barrier. Arctigenin, a Chinese herbal medicine,
T cell
IL-17 Protection
Neurons
was loaded into the nanosystem to reduce inflammation. The in vivo results showed that MSN-FC@ARC-G could attenuate inflammation at the injury site. Behavior and morphology experiments suggested that MSN-FC@ARC-G could diminish local microenvironment damage, especially reducing the expression of interleukin-17 (IL-17) and IL-17-related inflammatory factors, inhibiting the activation of astrocytes, thus protecting neurons and accelerating the recovery of SCI. Our study demonstrated that this novel, silica-based drug delivery system has promising potential for clinical application in SCI therapy. KEYWORDS Silica; Drug delivery; Spinal cord injury; Arctigenin; Astrocytes
Vol.:(0123456789)
13
23
Page 2 of 20
1 Introduction Spinal cord injury (SCI), a devastating condition, is becom‑ ing a serious health problem worldwide [1]. As a central pathological pr
Data Loading...
